KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Maria Debiec-Rychter, Raf Sciot, Axel Le Cesne, Marcus Schlemmer, Peter Hohenberger, Allan T. van Oosterom, Jean Yves Blay, Serge Leyvraz, Michel Stul, Paolo G. Casali, John Zalcberg, Jaap Verweij, Martine Van Glabbeke, Anne Hagemeijer, Ian Judson

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours'. Together they form a unique fingerprint.

Medicine & Life Sciences